Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALANASDAQ:EVLONASDAQ:SCPSNASDAQ:STAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00-95.0%$0.00$0.00▼$0.05N/A-2.5616,027 shs6,024 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.04$9K0.7413,476 shs5 shsSCPSScopus BioPharma$0.01$0.00$0.00▼$0.01$421K-0.242,238 shsN/ASTABStatera Biopharma$0.00$0.00$0.00▼$0.13$5K0.058,392 shs4,212 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-95.00%-83.33%0.00%-99.20%EVLOEvelo Biosciences0.00%0.00%0.00%0.00%-99.17%SCPSScopus BioPharma0.00%+3,233.33%+3,233.33%+3,233.33%+4,900.00%STABStatera Biopharma0.00%0.00%0.00%0.00%-83.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera Biosciences0.6363 of 5 stars0.01.00.04.50.60.00.0EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/ASTABStatera Biopharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A7/7/2025 (Estimated)SCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AEVLOEvelo Biosciences0.31%SCPSScopus BioPharmaN/ASTABStatera BiopharmaN/AInsider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%EVLOEvelo Biosciences1.02%SCPSScopus BioPharma5.10%STABStatera Biopharma5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataSCPSScopus BioPharma942.08 million39.94 millionNot OptionableSTABStatera Biopharma2053.30 millionN/ANot OptionableSTAB, SCPS, CALA, and EVLO HeadlinesRecent News About These CompaniesFed-up Minnesotans warn Tim Walz uses Midwest charm to drive far-left policies: ‘He will stab you in the back’August 10, 2024 | nypost.comThe Scientific and Technical Advisory BodyMay 22, 2024 | unesco.orgDog-walking NY couple turns table on would-be mugger who was hospitalized with stab wounds: videoMay 19, 2024 | foxnews.comPocket Bravery developer Statera Studio announces 2D platform fighter Shield Strike for PCMay 18, 2024 | gematsu.comBridgend: Wife begged ex-councillor to end stab attack - courtMay 8, 2024 | bbc.co.ukStatera BioPharma Inc Ordinary SharesApril 18, 2024 | morningstar.comCRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICAApril 12, 2024 | finance.yahoo.comArrests after man found with serious stab injuriesApril 7, 2024 | bbc.comPolice appeal after man found with stab injuriesApril 4, 2024 | bbc.comAEON Biopharma Inc.February 25, 2024 | wsj.comMereo BioPharma Group PLC ADR (MREO)January 30, 2024 | investing.comCrookes curry house knife used to stab teenager to deathDecember 14, 2023 | bbc.comLeeds stab death: Police name victim of Chapeltown attackDecember 9, 2023 | bbc.comTwo boys, 12, in court charged with Wolverhampton stab murderNovember 25, 2023 | bbc.co.ukWolverhampton: Two boys, 12, arrested over stab murder of manNovember 25, 2023 | bbc.co.ukARCA biopharma Inc ABIONovember 11, 2023 | morningstar.comCornell University student threatened to stab and rape Jewish students and ‘shoot up’ school, prosecutors sayNovember 10, 2023 | nbcnews.comPOINT Biopharma Global Inc Ordinary Shares PNTOctober 31, 2023 | morningstar.comElianne Andam died from ‘multiple stab wounds’ in ‘brutal’ attackOctober 29, 2023 | nypost.comNewport News mother dies by suicide while serving sentence for stabbing children, killing 1: HRRJOctober 27, 2023 | wtkr.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Utilities Stocks With Big Earnings, Balanced RiskBy Nathan Reiff | June 5, 2025View 3 Utilities Stocks With Big Earnings, Balanced RiskChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthIs Meta Plotting a Stablecoin Comeback Years After Libra's Flop?By Leo Miller | June 5, 2025View Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop?Best Utilities Stocks for Stability and Growth in 2025By Chris Markoch | May 21, 2025View Best Utilities Stocks for Stability and Growth in 2025STAB, SCPS, CALA, and EVLO Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0001 0.00 (-95.00%) As of 06/17/2025 09:31 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 06/18/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Scopus BioPharma NASDAQ:SCPS$0.01 0.00 (0.00%) As of 06/18/2025Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Statera Biopharma NASDAQ:STAB$0.0001 0.00 (0.00%) As of 06/18/2025 10:57 AM EasternStatera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish Cantor Boosts Rocket Lab Target to Street-High $35 Why Amazon Could Be About To Breakout To $250 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
